PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

Read it at Medical Xpress ↗

← Front page